Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Anteris Advances PARADIGM Trial as Quarterly Cash Outflow Reaches US$23 Million

AVR: $8.50 +0.00% · MC: $876M

Anteris reported net operating cash outflows of approximately US$23 million for the September quarter, mainly supporting clinical, regulatory and manufacturing work on its PARADIGM trial. Trial enrolment is progressing across active sites, with regulatory clearance and approvals after quarter-end extending the study into Germany and Australia; the company also took occupancy of a Minnesota facility intended to expand production capacity ahead of potential commercialisation.

Source announcements: 2026-11-11 09:12 to 2026-11-11 09:16 Sydney time
Story updated 2026-11-11 09:28 Sydney time
SourcesQuarterly Results Announcement and SEC Form 10-QResults for the Third Quarter of 2026
Comments